Physician profile
Andy S Jang
NPI 1386703031
$17,284.46
in general payments reported to CMS, 2019-2025
37 companies · $5,173 in 2025
The $5,173 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,436 · 2020: $442 · 2021: $1,025 · 2022: $2,105 · 2023: $6,283 · 2024: $821 · 2025: $5,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,050 · Food and Beverage: $3,614 · Travel and Lodging: $2,888 · Honoraria: $1,700 · Education: $25.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,050.00 |
| Food and Beverage | $3,613.86 |
| Travel and Lodging | $2,887.81 |
| Honoraria | $1,700.00 |
| Education | $25.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $3,970.54 | 2023 | Monoferric |
| Syndax Pharmaceuticals, INC. | $3,946.15 | 2025 | Revuforj |
| E.R. Squibb & Sons, L.L.C. | $1,674.10 | 2019-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $1,656.89 | 2019-2025 | Imfinzi |
| Daiichi Sankyo INC. | $1,400.00 | 2022-2025 | Vanflyta |
| Amgen INC. | $443.92 | 2019-2021 | |
| Abbvie INC. | $429.79 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $376.52 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $375.73 | 2021-2023 | Xpovio |
| Gilead Sciences, INC. | $286.68 | 2023 | |
| Genentech, INC. | $199.36 | 2024-2025 | Itovebi, Rituxan, Gazyva |
| Incyte Corporation | $195.66 | 2024-2025 | Jakafi, Pemazyre, Monjuvi |
| Blueprint Medicines Corporation | $177.81 | 2022-2023 | Ayvakit |
| Emd Serono, INC. | $162.20 | 2022-2023 | |
| Eisai INC. | $161.35 | 2022-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $149.14 | 2022 | |
| Pfizer INC. | $148.54 | 2020-2025 | |
| Servier Pharmaceuticals LLC | $124.99 | 2021 | |
| Glaxosmithkline, LLC. | $119.71 | 2022 | |
| Immunocore Limited | $108.14 | 2023-2025 | Kimmtrak |
| Genmab U.S., INC. | $105.74 | 2023 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $102.65 | 2019-2024 | Alunbrig |
| Seagen INC. | $99.59 | 2023 | Adcetris |
| Mirati Therapeutics, INC. | $98.35 | 2023 | Krazati |
| Janssen Scientific Affairs, LLC | $92.11 | 2023 | Tecvayli, Darzalex |
| Celgene Corporation | $84.01 | 2019-2023 | Pomalyst |
| Merck Sharp & Dohme LLC | $80.08 | 2019-2023 | |
| Kite Pharma, INC. | $79.00 | 2023-2025 | Yescarta |
| Jazz Pharmaceuticals INC. | $71.29 | 2023 | |
| Genzyme Corporation | $70.78 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $60.68 | 2020 | |
| Astellas Pharma US INC | $48.48 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $40.91 | 2023 | Epkinly |
| Genentech USA, INC. | $40.44 | 2023 | Phesgo, Lunsumio, Alecensa |
| Puma Biotechnology, INC. | $38.73 | 2019 | |
| Clinigen, INC. | $36.14 | 2019 | |
| Agios Pharmaceuticals, INC. | $28.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Jang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.